SBIR TOPIC 294 PHASE I - DEVELOPMENT OF GLYCOSYLATION - SPECIFIC RESEARCH

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$149,993.00
Award Year:
2011
Program:
SBIR
Phase:
Phase I
Contract:
N43CO110072
Agency Tracking Number:
N43CO110072
Solicitation Year:
2011
Solicitation Topic Code:
NCI
Solicitation Number:
n/a
Small Business Information
APTAKON INC.
3800 CAMBRIDGE ST, KANSAS CITY, KS, 66160-0001
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
809981108
Principal Investigator:
RICHARD SUDERMAN
(816) 510-7674
RJSUDERMAN@GMAIL.COM
Business Contact:
RICHARD SUDERMAN
(816) 510-7674
RJSUDERMAN@GMAIL.COM
Research Institution:
Stub




Abstract
The function of many cancer related proteins is modulated by modifications such as phosphorylation and glycosylation. The development of antibodies that recognize site-specific phosphorylation has vastly improved our understanding of signal transductionand cancer cell physiology and regulation. However, almost no available antibodies recognize site specific glycosylation, and in particular, N-acetylglycosamine modification of serines and threonines (O-GlcNAc). Possible reasons for this are poor immunogenicity in animals, or that antibodies are not appropriate for recognizing OGlcNAc in a site specific fashion. These limitations may make it extremely challenging to generate site-specific anti-OGlcNAc antibodies with sufficient affinity and selectivityto be useful research tools. A non-antibody-based approach has the potential to serve as an alternative method for generating affinity capture reagents that recognize site-specific OGlcNAc. Aptakon has developed a 14 kD protein scaffold with randomizablebinding loops that is not subject to the limitations described for antibodies. Aptakon aims to: screen phagemid libraries of this scaffold for binders to O-GlcNAc modified regions of cancer relevant proteins; generate applications data for these binders; optimize a master library for identifying O-GlcNAc modified peptides; and to produce standard operational procedures for isolation and characterization of these high affinity binders. This technology has the potential to spawn significant advances in cancer related signal transduction research similar to the advent of phospho-specific antibodies. These new products will have the potential to increase the productivity of researchers and thereby accelerate the development of drugs and diagnostic testsfor cancer.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government